Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**VB-C01** is an investigational, surgically implanted regenerative-medicine product developed by Viscofan for ischaemic left ventricular dysfunction and heart failure associated with ischaemic heart disease. It consists of a biocompatible collagen membrane seeded with allogeneic adipose-derived stem cells and is placed epicardially during coronary revascularisation surgery. The collagen scaffold is intended to localize and support the administered cells at the injured myocardium, while the cells are intended to promote myocardial repair through regenerative and paracrine effects. VB-C01 has been evaluated in first-in-human Phase 1 studies under the CARDIOMESH programme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VB-C01.